Stryker initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Stryker with an Outperform rating and $369 price target. The March 2026 cyberattack was an operational disruption, not a demand story, and hospital order books are full, 2026 guidance has been reaffirmed, and lost Q1 sales seem to have a clear recovery path through the remainder of 202